Physician profile
Marc C Silver
NPI 1285746610
$165,953.62
in general payments reported to CMS, 2019-2025
13 companies · $14K in 2025
The $14K reported for 2025 was more than what 92% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $79.40 · 2022: $8,507 · 2023: $360 · 2024: $143K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $156K · Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $156,293.31 |
| Food and Beverage | $849.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $156,307.37 | 2019-2025 | |
| Kls-Martin L.P. | $8,374.27 | 2022 | |
| Abbott Laboratories | $553.95 | 2019-2023 | Cardiomems |
| Medtronic, INC. | $221.50 | 2023-2025 | Avalus, Penditure |
| Atricure, INC. | $204.34 | 2023-2024 | |
| Stryker Corporation | $134.62 | 2025 | Mako |
| Baxter Healthcare | $45.50 | 2025 | Preveleak |
| Kestra Medical Technology Services, INC. | $26.41 | 2024 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $22.36 | 2019 | |
| Emd Serono, INC. | $22.26 | 2023 | Mavenclad |
| Pinnacle, INC | $21.69 | 2025 | |
| Lundbeck LLC | $19.35 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$335,826.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.